Development of an INR for rivaroxaban monitoring using plasma samples from patients

Thromb Res. 2020 Mar:187:122-124. doi: 10.1016/j.thromres.2020.01.009. Epub 2020 Jan 10.

Authors

James Zhang¹, Dominique Toupin¹, Martine Chicoine Lebel¹, Mark Blostein²

Affiliations

¹ Department of Medicine, Jewish General Hospital, McGill University, Montreal, Canada.
² Department of Medicine, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: mark.blostein@mcgill.ca.

PMID: 31986474
DOI: 10.1016/j.thromres.2020.01.009

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anticoagulants / therapeutic use
Factor Xa Inhibitors* / therapeutic use
Humans
International Normalized Ratio
Prothrombin Time
Rivaroxaban* / therapeutic use

Substances

Anticoagulants
Factor Xa Inhibitors
Rivaroxaban